Feasibility Studies for an RCT in anogenital psoriasis
Research type
Research Study
Full title
Feasibility Study (Focus Groups) for a randomised control trial to determine which topical agent is most efficacious in the treatment of anogenital psoriasis
IRAS ID
315227
Contact name
Dijon Millette
Contact email
Sponsor organisation
The Dudley Group NHS Foundation Trust
Duration of Study in the UK
0 years, 2 months, 30 days
Research summary
Psoriasis is a common inflammatory skin condition, which usually affects the extensor surfaces. Anogenital psoriasis can occur in isolation or combination with psoriasis in other sites. Anogenital psoriasis significantly impacts psychological and emotional wellbeing more so than any other subtypes of psoriasis. In light of this, we performed an extensive review of the existing evidence from currently available literature. We discovered that there is very little ascertainable data on the most efficacious topical therapy for anogenital psoriasis. Despite the use of biologics therapy becoming more widespread to treat psoriasis, many ano-genital psoriasis patients will not be eligible due to limited severity, resistant or intolerant to treatment, patient choice, absence of psoriasis in other areas and cost. Additionally, there exists no recognised quotidian tool to assess the impact and severity of psoriasis in high impact sites such as the ano-genital area.
It is based on these reasons that our research group strongly believes more research needs to be done into efficacious topical agents for ano-genital psoriasis. We propose probing into this by conducting feasibility studies in the form of focus groups to investigate the experiences and real-life outcome for patients with this condition who have a wealth of knowledge into the benefits, effects and safety profile of topical agents for ano-genital psoriasis.REC name
London - Fulham Research Ethics Committee
REC reference
23/LO/0414
Date of REC Opinion
8 Aug 2023
REC opinion
Further Information Favourable Opinion